We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BRBY:LSEBurberry Group plc Analysis

Data as of 2026-05-25 - not real-time

£1,124.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Burberry is trading at £1,124, roughly 15% below the DCF‑derived fair value of £1,275, suggesting a material upside despite an eye‑watering trailing P/E of 187. The stock sits just above its 20‑day SMA (£1,150) and below the 200‑day SMA (£1,180), while the MACD remains in bearish territory and the RSI hovers near 48, indicating a neutral to slightly bearish short‑term bias but no immediate oversold condition. Volume is on the rise and the 30‑day volatility is high at over 40%, yet the beta of 0.56 points to lower systematic risk relative to the market. Fundamentally, revenue growth is flat at 0.9% with a solid gross margin of 68%, but operating and profit margins are thin, and the company carries a high debt‑to‑equity ratio of 162, offset by strong cash reserves of £671 m. Analyst sentiment leans positive with a consensus “buy” and a median target of £1,350, though JP Morgan has reiterated an underweight rating, cautioning that the turnaround is still nascent. The recent full‑year results highlighted early progress in sales and margins, especially in the China market, but broader market weakness in the UK and soft Chinese trade data add headwinds. Given the brand’s premium positioning, global footprint, and a DCF upside, the stock appears modestly undervalued and positioned for a potential recovery if the operational improvements sustain.
The lack of dividend payments eliminates income‑focused appeal, while the modest ROE of 2.1% and free cash flow generation of £400 m suggest limited upside on a pure value basis. However, the forward P/E of 19.7 aligns more closely with growth‑oriented peers, and the consensus analyst targets imply a belief in a longer‑term earnings uplift. Investors should weigh the current technical softness and high valuation multiples against the brand’s resilience, improving cash conversion, and the upside indicated by the DCF model.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and neutral RSI suggest limited near‑term upside
  • Increasing volume but high short‑term volatility
  • Support level around £1,022 provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF upside of ~15% and forward P/E near 20
  • Analyst consensus “buy” with median target of £1,350
  • Early signs of turnaround in sales and margins, especially in China

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong brand equity in the luxury segment
  • Solid cash position versus debt, enabling strategic investments
  • Undervaluation relative to fair value and potential for sustained earnings growth

Key Metrics & Analysis

Financial Health

Revenue Growth0.90%
Profit Margin0.87%
P/E Ratio187.3
ROE2.14%
ROA3.07%
Debt/Equity161.52
P/B Ratio4.3
Op. Cash Flow£484.0M
Free Cash Flow£400.8M

Technical Analysis

TrendNeutral
RSI47.9
Support£1,022.50
Resistance£1,258.60
MA 20£1,150.08
MA 50£1,116.74
MA 200£1,180.22
MACDBearish
VolumeIncreasing
Fear & Greed Index91.7

Valuation

Fair Value£1,274.65
Target Price£1,299.91
Upside/Downside15.65%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.56
Volatility42.37%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.